Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.105
-0.015 (-1.34%)
Mar 11, 2025, 12:54 PM EST - Market open
Actinium Pharmaceuticals Stock Forecast
ATNM's stock price has decreased by -85.23% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Actinium Pharmaceuticals stock have an average target of 8.75, with a low estimate of 4.00 and a high estimate of 21. The average target predicts an increase of 691.86% from the current stock price of 1.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Actinium Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +261.99% | Mar 11, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $5 | Buy | Reiterates | $5 | +352.49% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +261.99% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $4 | Strong Buy | Maintains | $50 → $4 | +261.99% | Aug 6, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $5 | Strong Buy | Maintains | $30 → $5 | +352.49% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
193.12K
from 81.00K
Increased by 138.42%
Revenue Next Year
32.94M
from 193.12K
Increased by 16,957.05%
EPS This Year
-1.43
from -1.83
EPS Next Year
-0.95
from -1.43
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.2M | 61.1M | 98,700 | |||
| Avg | 193,117 | 32.9M | 47,940 | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1,372.8% | 31,534.8% | -99.7% | |||
| Avg | 138.4% | 16,957.1% | -99.9% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.30 | 0.17 | -0.89 | |||
| Avg | -1.43 | -0.95 | -1.14 | |||
| Low | -1.47 | -1.46 | -1.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.